Canada’s medical technologies sector is transforming healthcare through advanced diagnostics, surgical innovations, integrated health solutions, and other medical devices. Ayming partners with research teams, clinical organizations, and Medtech innovators secure strategic funding. We support device development, clinical validation, and sustainable growth in both Canadian and international markets.
Medical Technology (Medtech)
Addressing the key challenges
The medical technology (medtech) sector sits at the convergence of engineering, life sciences, and clinical application. It’s a field where innovation must meet stringent standards for safety, compliance, and performance. Yet many companies mistakenly believe that only market-ready devices or entirely successful prototypes qualify for government funding.
In reality, funding programs are designed to support experimentation. Early-stage prototyping, iterative testing, and even inconclusive trials that push the boundaries of medical technology are often eligible for financial support.
Unique R&D challenges in key innovation areas:
- AI-Driven Diagnostics: Effort focus on improving algorithm accuracy, reducing bias, and validating results across diverse patient populations.
- Wearable & Remote Monitoring Devices: Challenges include achieving miniaturization, extended battery life, and secure, reliable data transmission.
- Surgical Robotics & Automation: Enhancing precision, haptic feedback, and real-time imaging integration for complex procedures.
- Biocompatible Materials & Implantables: Ensuring long-term safety, stability, and sterilization durability within the human body.
- Point-of-Care Testing & Imaging: Accelerating turnaround times while maintaining accuracy and ease of use in varied clinical environments.
- Sustainability and Environmental Impact: Challenges to design devices with recyclable materials, energy efficiency, and reduced environmental footprint to meet growing sustainability standards.
These challenges demand rigorous R&D, supported by a comprehensive mix of funding opportunities, such as SR&ED tax incentives, government grants, and innovation loans. Whether you’re advancing AI-assisted diagnostics, next-generation implantable, or building connected care platforms, tailored funding options are available to help scale your innovation.
Navigating multiple funding sources while aligning research and development, engineering, and finance teams can be intricate. At Ayming, we streamline this process by assisting you in securing the best combination of government funding and tax incentives. Our team works alongside yours to maximize capital, diminish administrative burdens, and expedite innovations that improve patient outcomes.
How we can help maximize your results
We help biotechnology companies and CROs identify and claim all eligible SR&ED activities embedded in their research and development. From platform development, omics and personalized medicine to AI-driven analysis, precision medicine, and cell & gene therapy development.
Our comprehensive support includes:
- Technical Expertise and Project Framing: Many early-stage biotech firms lack the resources or financial expertise to effectively claim SR&ED. Clinical-stage companies struggle to claim SR&ED on outsourced work performed by local or international CROs. Our specialized consultants collaborate closely with your team to understand your R&D activities. This includes work in genomics, multi-omics analysis, AI model development, and clinical trial support. We then translate these efforts into compelling, compliant SR&ED narratives designed to maximize recoverable funding.
- Clarifying eligibility when working client-funded: Many CROs assume their contracted work isn’t eligible because it’s performed for clients. In reality, contractors, including CROs, can often claim SR&ED if they retain risk and conduct eligible R&D in Canada. This includes opportunities even when working with foreign sponsors or non-taxable entities. We help assess contract structures, intellectual property rights, and technical scope to determine what qualifies and how to structure future engagements for eligibility.
- Audit defense and compliance strategy: The CRA increasingly scrutinizes SR&ED claims, particularly in the biotechnology sector. We provide early warnings on audit trends and policy changes affecting the biotechnology companies and CROs, and if selected for review, we manage the end-to-end audit response to minimize business disruption.
Whether you’re advancing AI-driven genomics, developing next-generation therapies, or managing complex clinical trials, we translate your innovation efforts into impactful SR&ED claims that maximize financial return, and private investments, while ensuring regulatory compliance.
We assist biotechnology companies and CROs in accessing a comprehensive range of government funding options, including repayable innovation loans, non-dilutive grants, and strategic programs. Our expertise supports securing funding for high-impact research and development in areas that are often overlooked, such as personalized medicine, omics analysis, AI-driven drug discovery, and clinical trial.
Our mission is to secure the necessary capital to accelerate biotech innovation, support clinical development, and advance transformative therapies. We work closely with your leadership to align project objectives with federal and provincial priorities, such as precision medicine, biomanufacturing, and improved patient outcomes. This partnership helps develop persuasive applications that increase approval success.
Our comprehensive support includes:
-
Grant Applications
-
Pre-Application Strategy & Positioning
-
Government Relationships & Advocacy
-
Funding Landscape Insights & Strategy
-
Foreign Direct Investment (FDI) Funding Strategy
-
Post-Approval Compliance & Claim Support
Advancing AI genomics, developing novel therapies, or navigating clinical trials, we partner with you to craft a funding roadmap that powers innovation and propels growth.
More about Government Grants, Loans & Innovation Funding
Government Grants & Loans | Full-Service Support
We assist biotechnology companies and CROs in leveraging IP Box incentives to maximize the value of their intellectual property and innovation. These programs reduce the effective tax rate on income generated from eligible patents and technologies, freeing up resources to reinvest in R&D, advanced therapeutics, and clinical development initiatives.
Whether you’re developing platforms, AI-driven genomics tools, advancing cell and gene therapies, or managing complex clinical trials, we help you unlock the full potential of your intellectual property, creating a strategic funding roadmap that accelerates innovation and enhances financial efficiency.
Transforming the Medical Technology Industry
Our insights address the current challenges facing the medical technology and medical device industry, while offering forward-thinking solutions that drive innovation and shape the future of healthcare.
